Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Xolair omalizumab humanized monoclonal antibody against IgE regulatory update

The FDA's Pulmonary-Allergy Drugs Advisory Committee (PADAC) voted 11-0 that Xolair has a favorable risk benefit ratio in

Read the full 182 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE